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Polymer-drug conjugates are macromolecular drug carrier systems with active agents
attached as side substituents to a polymer backbone using an appropriate spacer. They
could be an effective way to prolong drug activity, minimize unfavorable side effects and
toxicity, decrease the required dose and increase the solubility of drugs (1). In addition,
polymer-drug conjugates have the ability to overpass some mechanisms of drug resis-
tance and the potential to elicit immunostimulatory effects. They can also alter the body
distribution of drugs and ensure adequate drug delivery to target cells or tissues. This is
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Two hydrosoluble conjugates of 17b-estradiol (ED) and
estradiol-17b-valerate (EV) with polyaspartamide polymer
were prepared and characterized. ED and EV were first
chemically modified and bound to poly[a,b-(N-2-hydro-
xyethyl-DL-aspartamide)]-poly[a,b-(N-2-aminoethyl-DL-as-
partamide)] (PAHA), a hydrosoluble polyaspartamide-
-type copolymer bearing both hydroxyl and amino groups.
ED was first converted to 17-hemisuccinate (EDS) and then
bound to PAHA. In the resulting conjugate PAHA-EDS,
the estradiol moiety was linked to the polymer through
a 2-aminoethylhemisuccinamide spacer. On the other
hand, EV was first converted to estradiol-17b-valerate-3-
-(benzotriazole-1-carboxylate), which readily reacted with
amino groups in PAHA affording the polymer-drug con-
jugate PAHA-EV. In the prepared conjugate PAHA-EV, the
estradiol moiety was covalently bound to the polyaspart-
amide backbone by carbamate linkage, through an ethy-
lenediamine spacer. The polymer-drug conjugates were
designed and prepared with the aim to increase water-
-solubility, bioavailability and to improve drug delivery
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particularly advantageous in cancer therapy since polymers accumulate in malignant cells
more readily than in healthy tissues, thus precluding undesirable side effects generated
by free drugs (2).
Polymers of polyaminoacid type are frequently used in polymer-drug conjugates be-
cause of their protein-like nature and biodegradability. Polymers of controlled molecular
mass and molecular mass distribution can be prepared by chemical or biosynthetic me-
thods. Polyaminoacid polymers with various side functional groups suitable for modifi-
cation and conjugation with active molecules are available (3). Among polyaminoacids,
polyaspartamide derivatives have been of special interest due to their excellent solubil-
ity, bioavailability, biocompatibility and favorable reactivity (1). Polyaspartamide conju-
gates with numerous drugs have been reported by our (4-6) and other research groups
(see, for example, refs. 7, 8).
Poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)]-poly[a,b-(N-2-aminoethyl-DL-aspartami-
de)] (PAHA) is a copolymer of polyaspartamide type that has been successfully applied
in the synthesis of several macromolecular prodrugs, including 17b-estradiol-3-benzoate
(9), diclofenac, fenoprofen (10) and broxuridine (11).
In this paper, we report the synthesis of two hydrosoluble PAHA conjugates of 17b-
-estradiol (ED) and estradiol-17b-valerate (EV), prepared with the aim to increase wa-
ter-solubility, bioavailability and improve drug delivery of this estrogen hormone.
In addition to serving as water-soluble prodrugs of estrogen, such conjugates have
potential uses as carriers for antitumor drugs. Polymer-drug conjugates with chemically
bonded steroid hormones have been explored as a means of targeting the active mole-
cule to tumor tissue due to the presence of tumor-associated receptors for steroid hor-
mones (12). It was thus proposed that estrogens chemically coupled to an active mole-
cule via an appropriate spacer could, upon binding to nuclear steroid receptors, direct
the active molecule into the nucleus of tumor cells (13).
EXPERIMENTAL
All one- (1H and APT) and gradient-selected two-dimensional (gCOSY, gHSQC and
gHMBC) NMR spectra were recorded at ambient temperature on a Bruker Avance DRX500
spectrometer (Bruker, USA) operating at 500.13 MHz for 1H and equipped with a 5-mm
diameter inverse detection probe and z-gradient. Sample concentration in DMSO d6 was
20 mg mL-1. TMS was used as the internal standard. Typical spectral conditions for one-
-dimensional 1H and 13C (APT) spectra were as follows: the spectra were recorded using
64 K data points and spectral widths of 7700 Hz and 32000 Hz for 1H and 13C experi-
ments, respectively; digital resolution was 0.12 Hz and 0.48 Hz per point, respectively.
The number of scans was 16 for 1H and 1000 for APT spectra. 2D gradient selected
COSY spectra and TOCSY spectra were acquired with a sweep width of 6600 Hz in both
dimensions using 2 K data points and 512 increments. Digital resolution was 6.50 Hz per
point in both dimensions. TOCSY spectra were obtained using the spin-lock time of 60
ms. The gradient selected inverse 1H–13C correlation experiments, gHSQC and gHMBC,
were recorded at 125.77 MHz using the acquisition matrix of 1 K × 256 with 32 scans and
processed with a 2 K × 1 K transformed matrix. The sweep width was 6600 Hz in f2 di-
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mension and 32000 Hz in f1 dimension for both experiments. Digital resolution was 3.25
Hz per point and 30.70 Hz per point in f2 and f1, respectively. HMBC spectra were re-
corded using transfer delay for the evolution of long-range C-H couplings of 60 ms. IR
spectra were recorded on a FT-IR Paragon 500 spectrometer (Perkin-Elmer, UK) and UV
spectra on a Hewlett Packard 8452A diode array spectrophotometer (Hewlett Packard,
Germany).
Dialysis was performed with Visking Dialysis Tubing 18/22 (Serva, Germany). For
thin layer chromatography, silica gel sheets Kieselgel 60 F254 (Merck, Germany) were used.
Solvent systems were cyclohexane/ethyl acetate 1:1 and 1:3, or chloroform. For spot de-
tection, iodine vapor and short-wave UV light were used. Column chromatography was
performed on silica gel 0.063-0.200 mm (Kemika, Croatia), with chloroform as eluent. Estra-
diol, estradiol-17b-valerate, benzotriazole, succinic anhydride, triphosgene and 1-ethyl-
-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDAC) were purchased from
Sigma-Aldrich (USA). All solvents were of analytical grade and were dried before use.
1-Benzotriazole carboxylic acid chloride (BtcCl, 1) was prepared from benzotriazole
and triphosgene following the procedure published previously (14).
Syntheses
Estradiol-17b-hemisuccinate (EDS, 2). – ES was prepared according to a modified pro-
cedure (15). A solution of 0.327 g (0.0012 mol) estradiol and 0.120 g (0.0012 mol) succinic
anhydride in 15 mL pyridine was refluxed for 14 h. An additional amount of 1.200 g
(0.012 mol) succinic anhydride was added in portions of 0.120 g approximately each hour.
The reaction mixture was poured into 600 mL water and the suspension was extracted
three times with ether. Organic layers were combined and washed with diluted HCl so-
lution (w = 2 %) and water until neutral, dried over anhydrous sodium sulfate and evapo-
rated to dryness. The residue was dissolved in 15 mL methanol and treated with a solu-
tion of 0.332 (0.0024 mol) potassium carbonate in 5 mL water and 15 mL methanol. The
reaction mixture was stirred for 24 h and evaporated. The crude product was mixed with
30 mL water and extracted three times with ether. Organic layers were combined, dried
over anhydrous sodium sulfate and evaporated under reduced pressure.
Estradiol-17b-valerate-3-(benzotriazole-1-carboxylate) (EVB, 3). – A solution of 0.036 g
(0.0002 mol) BtcCl (1) in 5 mL toluene was added dropwise to a solution of 0.071 g
(0.0002 mol) EV and 0.020 g (0.0002 mol) triethylamine (TEA) in 20 mL dry toluene. The
reaction mixture was stirred for 1 h at room temperature and evaporated under reduced
pressure. The analytically pure product 3 was obtained after column chromatography
(mobile phase: chloroform).
Poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)]-poly[a,b-(N-2-aminoethyl-DL-aspartamide)]
copolymer (PAHA, 4). – PAHA was synthesized by partial aminolysis of polysuccinimide
(PSI) with 2-aminoethanol and subsequently with ethylenediamine following a previou-
sly described procedure (11). Average molecular mass of PSI was determined by the vis-
cosimetric method following the Mark-Houwink equation [h] = 1.32 ´10–2 M0.76 (Mr =
55000). The molar ratio of PSI monomer to 2-aminoethanol was 3:2 and ethylenediamine
was used in excess in order to prevent cross-linking.
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PAHA-estradiol-3-benzoate-17b-hemisuccinate conjugate (PAHA-EDS, 5). – PAHA-EDS
conjugate was prepared by the coupling reaction of PAHA (0.095 g, 0.006 mol) and EDS
(2) (0.075 g, 0.002 mol) in the presence of EDAC (0.959 g, 0.005 mol) in a DMF/water/ac-
etone mixture (25:18:8, V/V/V) at pH 5. Reaction mixture was stirred for 72 h. Product 5
was purified by dialysis against water, followed by freeze drying. The purity of the pro-
duct was examined by TLC. Drug loading was determined by UV spectrophotometry at
280 nm from the calibration curve of estradiol (7 %).
PAHA-estradiol-17b-valerate conjugate (PAHA-EV, 6). – A solution of 0.108 g (0.0002
mol) of compound 3, 0.283 g (0.0028 mol) TEA and 0.094 g (0.0006 mol) PAHA in 20 mL
DMF was stirred for 72 h at room temperature. The solvent was evaporated under re-
duced pressure and the residue was triturated with acetone. Product 6 was filtered off,
dissolved in water, dialyzed for 3 days and freeze-dried. Drug loading was determined
by UV spectrophotometry at 280 nm from the calibration curve of estradiol (12 %).
RESULTS AND DISCUSSION
Two hydrosoluble conjugates of 17b-estradiol (ED) and its ester estradiol-17b-vale-
rate (EV) with poly[a,b-(N-2-hydroxyethyl-DL-aspartamide)]-poly[a,b-(N-2-aminoethyl-
-DL-aspartamide)] copolymer (PAHA, 4) were prepared and characterized. PAHA was
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Scheme 1
prepared following our synthetic procedure by partial aminolysis of polyssucinimide with
2-aminoethanol in a ratio 3:2 (calculated as PSI monomer unit) and followed by aminoly-
sis with an excess of ethylenediamine in order to prevent cross-linking (11). Prior to bin-
ding, ED and EV were chemically modified. ED was first converted to 17-hemisuccinate
(EDS, 2), a derivative bearing a free carboxylic group, which enabled binding to PAHA
by an amide bond. EDS was prepared in the reaction of ED with an excess of succinic
acid anhydride in pyridine (Scheme 1). In that reaction, both hydroxyl groups of ED re-
acted with anhydride forming a diester. By addition of potassium, the carbonate ester
bond at the phenolic group was cleaved. The coupling of EDS to PAHA was performed
in an EDS/PAHAmolar ratio 1:3, in the presence of a water-soluble carbodiimide EDAC.
In the resulting conjugate PAHA-EDS (5), the estrogen moiety was linked to the succi-
nate spacer by an easily cleavable ester bond.
EV was first converted to estradiol-17b-valerate-3-(benzotriazole-1-carboxylate)
(EVB, 3). Compound 3 was prepared from EV and 1-benzotriazole carboxylic acid chlo-
ride (BtcCl, 1), a versatile azole derivative useful in preparation of different classes of or-
ganic compounds. Compound 3 is a reactive carbamate, which readily reacted with
amino groups in PAHA affording the polymer-drug conjugate PAHA-EV (6). In conju-
gate 6, the estradiol moiety was covalently bound to the polyaspartamide backbone by
carbamate linkage, through an ethylenediamine spacer. Synthesis of conjugate 6 pro-
ceeded in DMF at room temperature, in the presence of TEA. The molar ratio of the reac-
tants was 1:3 (calculated as monomer units), which theoretically enabled substitution of
each amino group by the estradiol derivative. However, binding of the estradiol moiety
was not quantitative and the final conjugate 6 contained 12 % (m/m) of estrogen.
The synthesized compounds were characterized by 1H, 13C NMR, UV and IR spec-
troscopy (Tables I and II). The proton and carbon chemical shifts were assigned by the
combined use of one- (1H and APT) and two-dimensional NMR spectra (COSY, TOCSY,
HSQC and HMBC).
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Table I. Physico-chemical data for compounds 2, 3, 5, 6
Compd.
Yield
(%)
M.p.
(°C)
Drug
loading (%)
IR(KBr):nmax (cm-1)
Elemental analysis
calcd./found
C H N
2 58 167–169 -
3425, 3321, 2931, 1725,
1402, 1220, 1170, 1001, 874
70.94
70.78
7.58
7.66
–
–
3 45 165–166 –
2929, 2869, 1761, 1731,
1609, 1488, 1453, 1393,
1248, 1025, 749
71.83
71.54
7.03
6.96
8.38
8.70
5 62 – 7
3308, 1652, 1539, 1435,
1287, 1251, 1180, 1062, 668
–
6 53 – 12
3379, 3070, 2929, 1653,
1542, 1438, 1388, 1279,
1232, 1175, 1059, 1064, 668
–
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Table II. 1H and 13C NMR spectra of estradiol derivatives 2 and 3
Compd. 2 3
Atom 1H d (ppm) 13C d (ppm) 1H d (ppm) 13C d (ppm)
1 7.03 125.95 7.44 126.62
2 6.50 112.64 7.27 118.43
3 – 154.85 – 147.60
4 4.43 114.83 7.22 121.09
5 – 136.97 – 138.59
6 2.71 28.99 2.88 28.86
7 1.79, 1.26 26.74 1.67, 1.37 26.33
8 1.30 38.19 1.51 37.64
9 2.08 43.14 2.29 43.34
10 – 130.04 – 137.96
11 2.22, 1.30 25.76 2.36, 1.43 25.56
12 1.76, 1.30 36.32 1.76, 1.40 36.35
13 – 42.56 – 42.43
14 1.26 48.96 1.35 48.98
15 1.67, 1.35 22.69 1.71, 1.37 22.07
16 2.08, 1.49 26.98 2.11, 1.51 27.08
17 4.62 81.84 4.66 81.52
18 0.77 11.77 0.82 11.83
19 – 171.75 – 172.08
20 2.50 28.94, 28.73 2.31 33.39
21 2.50 – 1.53 26.64
22 – 173.31 1.31 21.50
23 – – 0.88 13.49
24 – – – 160.55
25 – – – 113.07
26 – – 8.29 119.73
27 – – 7.63 125.71
28 – – 7.81 130.24
29 – – 8.12 130.96
30 – – – 133.68
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Drug loading in the conjugates was estimated by UV spectroscopy using the cali-
bration curve for ED in ethanol/water 1:1 (V/V) at l = 280 nm (ED absorption maxi-
mum). Drug loading in conjugates 5 and 6 was 7 and 12 % (m/m), respectively. Both con-
jugates were freely soluble in water. Preliminary hydrolysis studies showed that the drug
could be released from macromolecular prodrugs after chemical hydrolysis in a wide pH
range, but detailed kinetic studies and evaluation of potential pharmaceutical uses still
remain to be done.
CONCLUSIONS
Estrogen hormone 17b-estradiol and its ester with valeric acid were linked to the
polyaspartamide-type polymer PAHA, providing hydrosoluble polymer-drug conjuga-
tes PAHA-EDS (5) and PAHA-EV (6). The conjugates differ in the type of spacer and in
drug loading. In conjugate 5, estradiol was linked to the spacer and then to the polymer
through the C-17 hydroxy group, whereas through the C-3 phenol group in conjugate 6.
The synthesized conjugates are potential estrogen prodrugs.
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S A @ E T A K
Makromolekulski prolijekovi. XIII. Vodotopljivi konjugati 17b-estradiola i
estradiol-17b-valerata s poliaspartamidnim polimerom
MARIJANA ZOVKO KON^I], BRANKA ZORC i PREDRAG NOVAK
U radu je opisana priprava i karakterizacija dvaju vodotopljivih polimer-lijek konju-
gata 17b-estradiola (ED) i estradiol-17b-valerata (EV) s poliaspartamidnim polimerom. ED
i EV su prvo kemijski modificirani i vezani na poli[a,b-(N-2-hidroksietil-DL-aspart-
amid)]-poli[a,b-(N-2-aminoetil-DL-aspartamid)] (PAHA), vodotopljivi poliaspartamidni
kopolimer s hidroksi i amino skupinama. ED je prvo preveden u 17-hemisukcinat (EDS),
a zatim vezan na PAHA. U nastalom konjugatu PAHA-EDS estradiolska komponenta
vezana je na polimer preko 2-aminoetilhemisukcinatne razmaknice. S druge strane, EV
je prvo preveden u estradiol-17b-valerat-3-(benzotriazol-1-karboksilat), koji reagira s ami-
no skupinama u PAHA daju}i polimer-lijek konjugat PAHA-EV. U tom je konjugatu es-
tradiolska komponenta kovalentno vezana na poliaspartamidnu okosnicu karbamatnom
vezom, preko etilenediaminske razmaknice. Polimer-lijek konjugati estradiola dizajnira-
ni su i pripravljeni sa ciljem da se pove}a topljivost i bioraspolo`ivost te isporuka tog
lipofilnog estrogenog hormona.
Klju~ne rije~i: estradiol, poliaspartamid, poli[a,b-(N-2-hidroksietil-DL-aspartamid)]-poli[a,b-(N-2-ami-
noetil-DL-aspartamid)], polimer-lijek konjugat
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